When a knee replacement is not the only option

Being told you need a knee replacement raises an immediate practical question: is that the only path forward? For a growing number of patients with Kellgren-Lawrence Grade III or IV osteoarthritis — the range where joint surfaces are substantially degraded and replacement is most commonly recommended — ChondroFiller injection is now being evaluated as a joint-preservation alternative before that decision is made.

The injectable scaffold pathway is specifically designed for advanced, diffuse joint wear, not only for the isolated focal defects that cartilage repair has traditionally addressed. Rather than requiring a prepared surgical bed, ChondroFiller is delivered as an outpatient, ultrasound-guided injection that coats degenerated articular surfaces with an acellular Type I collagen scaffold, recruiting the patient's own progenitor cells to support repair from within. The comparison with knee replacement is about treatment choice at a decision point — not an assertion that the two approaches are clinically equivalent.

Suitability is not automatic. Specialist assessment, including MRI and weight-bearing X-ray to confirm KL grade and joint mechanics, is required before any candidacy decision can be made. This article sets out what that assessment involves and who tends to benefit.

How ChondroFiller works on a heavily worn joint surface

Once injected under ultrasound guidance, ChondroFiller — a CE-marked Class III medical device composed of acellular, murine-derived Type I collagen — self-gels within minutes, forming a stable viscoelastic scaffold directly on the articular surface. The action is top-down: rather than filling a surgically prepared defect cavity from below, the scaffold drapes across and adheres to degraded cartilage as a protective cushion. This is precisely why advanced, diffuse wear does not disqualify the joint. There is no upper limit on surface area for the injection pathway; a single delivery can coat the full articular surface in one session.

The regenerative process that follows is described as acellular matrix-induced chondrogenesis. Progenitor cells — drawn chemotactically from the surrounding synovium and subchondral bone — migrate into the collagen matrix. Once embedded, they mature into chondrocyte-like cells and progressively replace the degrading scaffold with native cartilage tissue. ChondroFiller provides the structural and biological environment; the patient's own cells carry out the repair.

Two comparisons help frame this clearly. Hyaluronic acid viscosupplementation lubricates and temporarily cushions the joint but offers no structural scaffold and does not recruit repair cells — it is palliative, not regenerative. Surgical cartilage repair techniques require a debrided, healthy bone bed, arthroscopic portals, and theatre admission; they are suited to isolated focal defects with intact surrounding cartilage, not to the diffuse wear pattern that defines KL Grade III/IV osteoarthritis. The injection pathway sidesteps both constraints.

Who is — and is not — a suitable candidate

The injection pathway carries no upper age limit. Active adults in their 60s, 70s, and beyond — often those who have been told joint replacement is their next step — represent the population it is specifically designed to serve, provided the joint's mechanical environment is stable.

That last proviso is the decisive factor in candidacy. Three structural conditions, if untreated, are contraindications:

• Significant malalignment — marked varus (bow-legged) or valgus (knock-kneed) deformity redirects load abnormally and will continue to drive cartilage loss regardless of what is placed on the articular surface.
• Untreated ligamentous instability — a structurally unsound joint cannot protect a scaffold from the shear forces that would displace or degrade it prematurely.
• An active meniscal deficit driving wear — where a deficient or absent meniscus is the primary cause of ongoing cartilage loss, the source of the problem remains unaddressed.

ChondroFiller addresses the cartilage surface. It cannot correct the biomechanical cause of wear, and where that cause is active and untreated, the scaffold's benefit may be substantially limited. These are not minor caveats; they reflect the distinction between a joint that has worn heavily and a joint that is mechanically unsound at a structural level. The two situations call for different treatment priorities.

A history of being advised to have a knee replacement is not itself a contraindication. It is, however, the start of an evaluation rather than a confirmed yes. MRI to characterise the cartilage, combined with a weight-bearing X-ray to assess the mechanical axis, is mandatory before candidacy can be confirmed. Symptom severity alone is not a sufficient basis for proceeding to treatment.

The imaging assessment before injection

Two types of imaging are requested before candidacy can be confirmed: a weight-bearing X-ray and an MRI of the affected joint. Each serves a distinct clinical purpose.

The weight-bearing X-ray is taken with the patient standing, so it reflects the joint under load rather than at rest. This is the scan that confirms the Kellgren-Lawrence grade — the degree of joint-space narrowing — and reveals the mechanical axis running from hip through knee to ankle. Malalignment detected here is one of the structural factors that can affect whether the scaffold will be effective.

MRI provides the soft-tissue detail the X-ray cannot: cartilage thickness across the full joint surface, the condition of the subchondral bone beneath it, meniscal integrity, and ligamentous stability. These findings map directly onto the candidacy criteria already described — stable joint mechanics are required, and MRI is the tool that confirms or questions them.

Together, the two scans also guide how treatment should be structured. A joint showing moderate cartilage loss with healthy surrounding soft tissue suggests a different clinical approach from one with extensive surface degradation and a significant synovial component. Imaging makes that distinction objectively — rather than on the basis of symptoms or a previous clinical opinion — and allows the treating clinician to match the protocol to what the joint actually requires.

Treatment protocols for KL Grade III and IV knees

Three documented treatment tiers apply once imaging confirms an advanced KL Grade III or IV joint and the mechanical prerequisites are met.

Standalone ChondroFiller injection serves as the starting point for earlier or milder presentations within the advanced-OA spectrum. The injectable collagen scaffold is placed under ultrasound guidance as a single outpatient appointment; guide cost is from £3,000. For some patients, this alone may be sufficient to provide both structural support and a regenerative stimulus.

The Dual Injection protocol is designed for advanced or end-stage KL III/IV OA. It combines two products delivered in a single in-clinic session: 2.3 mL of ChondroFiller applied to the articular bone ends, and 6 mL of Arthrosamid — a polyacrylamide hydrogel — applied to the synovium. The two components work through entirely different mechanisms and should not be treated as equivalent. ChondroFiller is a temporary, regenerative acellular scaffold that recruits the patient's own cells to promote endogenous repair; Arthrosamid is a permanent hydrogel cushion that integrates into the synovial membrane and provides mechanical support without cartilage regeneration. Each product is used here for a distinct purpose within the same joint. Guide cost is £6,000.

The Tri-Active Therapy adds autologous mesenchymal stem cells — sourced from bone marrow, adipose tissue, or ear cartilage — to the ChondroFiller and Arthrosamid combination, targeting the most severe 'impossible' joint presentations where additional cellular signalling is considered appropriate. Guide cost is £11,000.

A Longitudinal Lifetime Program is offered alongside any of these protocols: annual peptide support, yearly MRI monitoring, and biannual ChondroFiller top-up injections with the aim of sustaining structural preservation over time.

All guide costs are confirmed at consultation following imaging review. Protocol selection is a clinical decision driven by the imaging findings, not patient preference alone.

What the evidence shows — and where the limits are

Published ChondroFiller data from more than 19,000 cases worldwide records IKDC score improvements of approximately 30 points in the knee, MOCART MRI regeneration scores of 70 to 87, and a complaint rate of approximately 0.06%. Those figures come primarily from focal cartilage defect populations, where the evidence base is most developed.

The diffuse KL III/IV injection pathway covered in this article represents a newer clinical paradigm. Supporting data sits with clinic experience and manufacturer documentation rather than independent randomised controlled trials — a distinction patients weighing their options should understand plainly, not in the small print. Arthrosamid, the second component in the Dual Injection protocol, brings two-to-three-year registry cohorts in knee OA that reinforce the case for the combined approach, but specific RCT evidence for the pairing in diffuse advanced OA is not yet available.

For patients who are suitable, the injection may defer or avoid knee replacement — but what that looks like over five or ten years, and in what proportion of patients, has not yet been quantified in the peer-reviewed literature for this indication specifically. The published case volume establishes a consistent safety profile and a pattern of functional improvement; the longer-term replacement-avoidance question is what growing clinical experience is expected to answer.

Candidacy assessment, with current MRI and weight-bearing X-ray reviewed by a specialist, is the appropriate next step. Professor Paul Y. F. Lee leads that review at London Cartilage Clinic; appointments can be arranged at londoncartilage.com.